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Balkan endemic nephropathy (BEN), an environmental form of aristolochic acid
nephropathy is characterized with later onset and milder forms of hypertension (HT).
Thus, we hypothesized that arterial stiffness progresses slower in BEN patients resulting
in lower CV mortality. A total of 186 hemodialysed (HD) patients (90 BEN, 96 non-BEN;
67.3+ 13.0 years) were enrolled and followed-up for 25 months. Brachial blood pressure
(BP) and pulse wave velocity (PWV) were determined before mid-week dialysis. BEN
patients were older (72.1 ± 37.1 vs. 62.8 ± 15.1; p < 0.001), had shorter duration of
HT prior commencement of HD than non-BEN patients (36 vs. 84 months; p < 0.001).
There were no differences in BP, but BEN patients were treated with less antihypertensive
drugs (p < 0.01). BEN patients had lower PWV values at baseline and at the end of
follow-up period despite being chronologically older (p < 0.001). Baseline PWV > 10
m/s was associated with higher risk for CV mortality (aHR 1.8 [1.4, 2.4]). In multivariate
analyses BEN was predictor of lower PWV. During the follow-up period significantly less
CV deaths were observed in BEN vs. on-BEN patients (12 vs. 31; p= 0.001). CVmortality
adjusted for other risk factors was significantly lower in BEN group (aHR 0.2 [0.1, 0.5]).
Overall BEN patients had longer mean survival time on HD (22.3 vs. 18.2 months; p <
0.001). Observed slower vascular aging (i.e., lower PWV) in BEN patients compared to
other ESRD patients is related to the later onset of HT and milder stages of HT during
predialytic clinical course and better control of BP and phosphate during HD.
Keywords: Balkan endemic nephropathy, aristolochic acid nephropathy, arterial stiffness, chronic hemodialysis,
chronic kidney disease, pulse wave velocity
INTRODUCTION
Cardiovascular disease (CV) is the most important cause of morbidity and mortality in chronic
kidney disease (CKD) (1–6). It is well-established that the most characteristic aspect of arterial
disease in CKD/ESRD is premature vascular aging. Mean arterial pressure and age are most
important risk factors for increased arterial stiffness. Blacher et al. found increased pulse wave
velocity (PWV), to be a predictor of all-cause mortality and CV mortality in patients with ESRD
(7). This was confirmed by other authors analyzing data on patients in different CKD stages (3–9).
Higher values of PWV were found already in the early stages of CKD and it was reported that
arterial stiffness is also an independent risk factor for progression of CKD starting from CKD stage
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3 (10–12). On the other hand, it was shown that improving PWV
is associated with better survival in CKD patients independently
of blood pressure (BP) level (3, 7, 8). In patients with autosomal
dominant polycystic kidney disease arterial stiffness is evident
before the onset of hypertension and decline of eGFR, so this
form of CKD was proposed to be a case of exaggerated early
vascular aging (13). It seems that different forms of CKD
differ in arterial stiffness and progression of vascular aging.
Balkan endemic nephropathy (BEN) is chronic tubulointerstitial
nephropathy frequently associated with upper urothelial cancers.
Recently, it was proven that BEN is an environmental form
of worldwide present aristolochic acid nephropathy (14–17).
Later onset of hypertension during the predialytic clinical course
and mild stages of hypertension were reported to be important
features of BEN (15, 17–20). The most plausible explanation is
salt wasting. As mild and labile hypertension was occasionally
observed in BEN and became more frequent only in advanced
stages of CKD, the aim of our study was to determine possible
differences in arterial stiffness between BEN and non-BEN
patients undergoing chronic dialysis. Furthermore, we proposed
that patients with BEN have lower CV morbidity and mortality
than non-BEN ESRD patients. To test this hypothesis we
analyzed PWV and clinical course of BEN and non-BEN patients
undergoing chronic hemodialysis.
MATERIALS AND METHODS
This was a prospective, longitudinal follow-up study of 25
months duration. In total, 186 patients were recruited from
three dialytic units and two countries (General Hospital “Dr.
Josip Bencˇevic´” Slavonski Brod, Croatia; General Hospital Odžak,
Bosnia and Herzegovina; and University Hospital Centre Zagreb,
Croatia). The participation in the study was approved by the local
Ethical Committees. Inclusion criteria were: undergoing chronic
hemodialysis for at least 3 months and signed informed consent.
Exclusion criteria were: atrial fibrillation or other chronic
arrhythmias, recent stroke (<6 months), transitory ischemic
attack (TIA) or myocardial infarction (<6 months), congestive
heart failure (NYHA III-IV), significant hemodynamic instability
during the dialysis, presence of old artery-venous anastomoses at
contralateral arm of the currently used one. Diagnosis of BEN
and classification of subjects were done as described previously
in the consensus document (16). At baseline, there were 90
BEN patients (37 men, 53 women) and 96 non-BEN patients
(48 men, 48 women). In the non-BEN group the most frequent
causes of ESRD were diabetes (26%) and hypertension (21.8%)
followed by chronic glomerulonephritis (16.6%) and autosomal
dominant polycystic kidney disease (8.3%). Diabetes was more
frequently diagnosed in non-BEN than in BEN group (21 vs.
5; p = 0.001). Although at baseline substantially more patients
in non-BEN group had hypertension (90 vs.79), coronary heart
disease (32 vs. 22) and left ventricular hypertrophy (67 vs. 58)
differences did not reach statistically significant level (p > 0.05).
BEN patients had significantly shorter duration of hypertension
prior commencement of hemodialysis than non-BEN patients
[36 (12–84) vs. 84 (60–120)months; p< 0.001];. During the study
period they were treated with significantly less antihypertensive
drugs (1.22 ± 0.93 vs. 2.27 ± 1.32; p < 0.001), and were
much more frequently controlled with monotherapy than non-
BEN patients (43 vs. 21%; p = 0.0001). Non-BEN patients
were treated more frequently with beta blockers, alpha blockers,
loop diuretics, moxonidine, and minoxidile than EN patients
(p < 0.001). There were no differences in frequency of usage
of ACE inhibitors, ARBs, and calcium channel blockers (p >
0.05). Statins were used more frequently in non-EN group (27
vs. 13%; p = 0.02). Later in conducted analyses we failed to
find signicicant impact of used antihypertensive class on the
main findings i.e., on arterial stiffness possibly because most of
non-BEN patients were treated with various drugs combination.
All patients were on erythropoietin therapy and folic acid (B9),
82% were treated with calcitriol while 78% of patients were
on phosphate-binders therapy (CaCO3 and sevelamer). Patients
were dialyzed three times a week with standard bicarbonate
hemodialysis solutions and synthetic dialysers, with blood flow
rates of 300–350 ml/min and dialysate flow rates of 500–800
ml/min, aiming at a dialysis dose Kt/V > 1.2. There were no
differences in type of vascular access between BEN and non-BEN
group.
At the end of follow up period there were 52 BEN patients (20
men, 32 women) and 45 non-BEN patients (22 men, 23 women)
non-BEN patients. Death was recorded in 28 and 37 BEN and
non-BEN patients, respectively (31 vs. 39%; p= 0.29). During the
study period 24 patients undergone kidney transplantation with
no difference in proportion of patients between BEN vs. non-
BEN groups (11.1 vs. 14.5%, p = 0.45). Transplanted patients
were excluded from the cohort and analyses at the end of
follow-up.
Data on medical history and medication were collected from
hospital records. Total serum cholesterol, triglycerides, glucose,
iron, uric acid, potassium, calcium, phosphate, red blood cell
count, hematocrite, hemoglobin were analyzed from fasting
blood samples. All patients were studied on themid-week dialysis
day after a 2-days interdialytic interval. Body mass index (BMI)
was calculated as dry weight divided by the square of body height.
The mean value of three measurements of the post-dialytic body
weight was defined as dry weight. Brachial BP was measured
before dialysis using Omron M6 device (Kyoto, Japan) in sitting
position and was determined as mean of three measurements
at the non-fistula arm. PWV and aortic augmentation index
(Aix), were assessed by Tensiomed Arteriograph (Medexpert
Ltd., Budapest, Hungary), a computerized device using an
oscillometric method which simultaneously measure brachial
BP, PWV and Aix. PWV and Aix were determined before
dialysis as a mean of three measurements at the non-fistula
arm. All measurements which were taken by the same physician
(V.P.) in a quiet room after resting at least 15min before
the measurements. PWV value >10 m/s was used as a
cut-off value as recommended by the European Society of
Hypertension/European Society of Cardiology guidelines (21).
Pulse pressure amplification was determined as an absolute
difference between brachial and central pulse pressure while pulse
pressure amplification ratio was determined as a ratio between
brachial and central pulse pressure.
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Statistical analysis was performed using SPSS version 23.0
(IBM Corp., USA). Normality of data distribution was tested
using Kolmogorov-Smirnov test. Preliminary analyses were
performed to ensure no violation of the assumptions of
normality, linearity and homoscedasticity. Categorical data
were expressed as numbers and frequencies. Correlations
were obtained using Pearson’s test for normally distributed
variables and Spearman rank correlation for non-normally
distributed variables. Normally distributed variables were
presented as means ± standard deviations and Student’s t-test
for independent samples was used for comparisons between
two groups. Non-normally distributed data were presented as
median and interquartile range and Mann-Whitney U-test was
used in comparison between two groups. Baseline-to-follow-
up comparisons were done using Student’s t-test for paired
samples and Wilcoxon test. Categorical variables were compared
using χ2-test. Survival analysis was done with Kaplan-Meier
curves which were tested with log-rank test while hazard
ratios were estimated with Cox proportional hazards regression.
Multiple linear regression was used to explore the influence
of different variables on PWV, while logistic regression was
used for categorical dependent variables. We constructed three
linear regression models to assess independent associations
of multiple independent variables with PWV. In Model 1
we included variables known to be associated with arterial
stiffness: age, gender, mean arterial pressure (MAP), hematocrite,
ultrafiltration, vitamin D dose, phosphate binders dose, CaxP,
vascular access type, heart rate, and BEN status (yes/no). Model
2 included, in addition to all variables in Model 1 those further
related to the dialysis: dialysis vintage, Kt/V, sevelamer (yes/no),
and erythropoietin dose per kilogram of weight. Model 3 was
additionally adjusted for established CV risk factors: BMI,
smoking (yes/no), hypertension (yes/no), and DM (yes/no). A p
< 0.05 (two-sided tests) was considered significant.
RESULTS
Demographic and clinical characteristics of enrolled patients at
baseline and the end of follow-up are shown in Table 1. There
were no differences in gender and smoking status between BEN
and non-BEN groups. Importantly, BEN patients were older at
baseline and the end of follow-up (both p < 0.01). They were
also older when started with dialysis (p < 0.001). No significant
differences were observed in dialysis vintage. Obesity and visceral
obesity were more frequently present in non-BEN group. There
were no differences in dialytic parameters between two groups
beside ultrafiltration which was significantly higher in non-BEN
group (p < 0.001). We failed to detect differences in daily
phosphate binder, calcium load, vitamin D weekly dose, and
usage of sevelamer between two groups. As shown in Table 1
at baseline and at the end of follow-up BEN patients had lower
values of serum phosphate, calcium, product of calcium and
phosphate, and iPTH.
There were no differences in brachial BP and pulse pressure
values between BEN and non-BEN patients at baseline and at the
end of follow-up (Table 2). PWVwas significantly slower in BEN
patients at baseline and at the end of follow-up (both p < 0.01).
When adjusted for the same confounders included in Model 3
of linear regression PWV was still slower in BEN vs. non-BEN
patients (p < 0.01). On univariate analysis PWV was correlated
with AIx (r = 0.236; p = 0.001), dialysis vintage (r = 0.143;
p = 0.05), duration of dialysis (r = −0.304; p < 0.001), systolic
BP (r = 0.209, p = 0.004), diastolic BP (r = 0.188, p = 0.01),
pulse pressure (r = 0.158, p = 0.03), MAP (0.212, p = 0.004),
central systolic BP (r = 0.231, p = 0.001), central pulse pressure
(r = 0.244, p = 0.001), and age in non-BEN patients (r = 0.31;
p = 0.04). In all three linear regression models BEN was the
strongest predictor of lower PWV (β=−0.525, β=−0.508, and
β = −0.453, all p < 0.005). Additionally, in Model 1 (adjusted
R2 = 0.212) MAP (β = 0.307, p = 0.005) showed positive
association with PWV. In Model 2 (adjusted R2 = 0.288) MAP
(β = 0.239, p = 0.05), age (β = 0.333, p = 0.04), hematocrite
(β = 0.294, p = 0.03), and weekly/weight erythropoietin load
(β= 0.293, p= 0.01) were positively associated with PWV.Model
3 (adjusted R2 = 0.306) showed positive significant associations
of PWV with MAP (β = 0.267, p = 0.04), age (β = 0.317,
p = 0.01), and weekly/weight erythropoietin load (β = 0.246,
p= 0.05). On logistic regression, non-BEN patients had adjusted
OR (adjusted as in Model 3 of linear regression) for having PWV
> 10 m/s of 6.63 [2.19, 20.09] compared to BEN patients.
As shown in Table 3, in all decades lower average PWV values
were found in BEN patients compared to non-BEN group. This
is in line with the result on lower percentage of BEN patients
with PWV values above the referral values compared to non-
BEN patients what was found in all decades. In the BEN group
only one patient was younger than 50 years (decade 40–49 years).
Mean survival time on dialysis was longer in BEN group than
in non-BEN group [22.3 (95% CI 21.2, 23.5) vs. 18.2 (95% CI
16.4, 20.0) months, p < 0.001]. Non-BEN patients died more
frequently from CV events than BEN patients [31 (83.7%) vs.
12 (42.8%); p = 0.001]. Stroke, myocardial infarction and heart
failure were causes of deaths in 21.6, 24.3, and 38.8% in non-BEN
patients, respectively; and in 14.2, 10.7, and 17.8% BEN patients,
respectively. There was a marginally significant difference in all-
cause mortality between BEN and non-BEN patients (35.0 vs.
45.1%, HR 0.63 [0.39, 1.02], log-rank p = 0.057) which became
significant after adjustment for multiple risk factors and probable
confounders (listed in Model 3 of linear regression) (aHR 0.36
[0.17, 0.79]) (Figure 1). CV mortality was significantly lower in
BEN group (15.0 vs. 37.8%, HR 0.32 [0.18, 0.59], log-rank p =
0.0004; aHR 0.17 [0.06, 0.49]) (Figure 1). Baseline PWV > 10
m/s was associated with higher adjusted hazard for both all-cause
(aHR 2.14 [1.15, 3.97]) and CV mortality (aHR 1.88 [1.42, 2.49])
(Figure 2).
DISCUSSION
The most important result obtained in this study is finding that.
BEN patients undergoing chronic hemodialysis had significantly
lower PWV values at baseline and at the end of follow-up
period than non-BEN patients despite being significantly older
than non-BEN patients. The most plausible explanation is later
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TABLE 1 | Demographic, clinical, and laboratory data of enrolled patient at baseline and at the end of follow-up.
Baseline Follow-up
BEN Non-BEN p BEN Non-BEN p
Number of patients 90 96 52 45
Men/women 37/53 48/48 0.285 20/32 22/23 0.407
Age (years) 73 (68–78) 66 (54–75) <0.001 75 (71–78) 68 (56–75) 0.002
Age on start of dialysis (years) 67 (62–72) 57.5 (42.3–68.8) <0.001 69 (64–74) 60 (45.2–70.2) <0.001
Body height (cm) 165 + 8 168 + 10 0.036 165 + 7 167 + 8 0.18
Body weight (kg) 63 + 12 70 + 14 <0.001 62 + 10 68 + 13 0.014
Body mass index (kg/m2) 23.1 + 3.6 24.9 + 4.4 0.003 22.9 (19.2–29.3) 24.8 (20.1–31.2) 0.02
Waist circumference (cm) 78 (70–84) 82 (78–91) <0.001 77 (69–85) 82 (74–90) 0.009
Smokers (%) 13.3 13.5 0.96 11.2 11.5 0.92
Dialysis vintage (months) 68 + 49 82 + 63 0.09 99 + 52 102 + 61 0.83
Vascular access (A-V fistula/CVC) 73/17 72/24 0.31 40/12 38/7 0.28
Duration of dialysis (h) 4.3 (4.0–4.5) 4.0 (3.5–4.5) 0.61 4.2 (3.7–4.7) 3.8 (3.3–4.3) 0.21
Ultrafiltration (ml) 3,500 (2,500–4,000) 4,000 (3,500–4,000) <0.001 3,220 (2,700–3,700) 3,620 (3,000–4,000) <0.001
Residual diuresis (ml) 330 (240–420) 380 (310–470) 0.43 335 (285–385) 302 (250–350) 0.69
Kt/V 1.3 + 0.4 1.2 + 0.3 0.68 1.3 + 0.4 1.2 + 0.3 0.58
Weekly/weight erythropoietin load (IU/kg) 134 + 54 118 + 47 0.07 124 + 24 123 + 21 0.74
Daily phosphate binder calcium load (g/day) 3.2 + 1.6 2.8 + 1.6 0.28 2.1 + 2.01 2.1 + 2.1 0.88
Sevelamer (%) 16.6 27.1 0.08 17.9 29.1 0.07
Weekly vitamin D load µg/week 0.8 + 0.5 0.8 + 0.7 0.99 0.6 + 0.5 0.8 + 0.4 0.19
RBC (1012/l) 3.6 (3.2–3.9) 3.3 (3.1–3.6) 0.001 3.3 (3.1–3.7) 3.5 (3.3–3.8) 0.19
Hemoglobin (g/l) 115 (108–127) 108 (100–115) <0.001 113 (102–124) 111 (102–124) 0.68
Serum calcium (mmol/l) 2.2 ± 0.1 2.3 ± 0.2 0.23 1.2 (1.1–2.2) 2.27 (2.2–2.3) <0.001
Serum phosphate (mmol/l) 1.3 ± 0.4 1.6 ± 0.4 <0.001 1.2 ± 0.2 1.4 ± 0.4 0.014
Ca × P 3.1 ± 1.1 3.7 ± 1.1 <0.001 2.1 ± 1.1 3.4 ± 1.2 <0.001
iPTH (pmol/l) 10.4 (4.5–19.6) 20.2 (12.0–50.0) <0.001 18.4 (8.0–28.8) 32.7 (9.6–79.0) 0.013
Serum glucose (mmol/l) 5.3 (4.9–6.3) 5.5 (4.6–6.8) 0.88 5.7 (5.2–6.4) 5.7 (5.2–5.6) 0.55
Total serum cholesterol (mmol/l) 4.6 (4.1–5.1) 4.9 (3.9–5.2) 0.90 4.6 ± 1.1 4.1 ± 1.1 0.03
Serum triglycerides (mmol/l) 1.8 (1.3–2.3) 2.0 (1.8–2.3) 0.035 1.26 (0.99–1.81) 1.17 (1.02–2.12) 0.96
Serum uric acid (µmol/l) 322 (288–352) 317 (282–355) 0.61 346 ± 64 325 ± 59 0.09
BEN, Balkan endemic nephropathy; A-V, fistula–arterio-venous fistula; CVC, central venous catheter; iPTH, intact parathormone; results are shown as mean± SD or median (interquartile
range).
onset and milder forms of hypertension during the predialytic
clinical course of BEN, which was also observed by other
authors (14, 19, 20). Lower PWV in BEN patients could be
a biomarker of slower vascular aging and consecutive slower
progression of CKD and lower CV risk in this group of ESRD
patients. BEN patients were significantly older than non-BEN
patients when started with dialysis what is in line with reports
from other BEN dialytic units (22, 23). Recently in surveys
conducted in Croatian endemic area we found that in predialytic
period CV mortality was significantly lower in BEN than in
non-BEN patients (Jelakovic´ and Premužic´, 2018, unpublished
data). In this study hypertension was better controlled with
less antihypertensive drugs in BEN patients compared to non-
BEN patients. Furthermore, phosphate, calcium, and iPTH values
were better controlled in BEN patients compared to other
ESRD patients what contributed to less vascular calcification
and slower progression of arterial stiffness during the follow-
up period. In both groups, PWV was strong independent
predictor of CV mortality, particularly deaths from stroke
and heart failure (Figure 2). Our results are in agreement
with previously published data confirming that increased aortic
stiffness i.e., PWV is a strong independent predictor of CV
mortality in CKD/ESRD patients (8, 24). Importantly, in BEN
group PWV values were lower than in non-BEN patients
contributing to the lower risk for CV mortality. Chirinos et
al. observed that increased arterial stiffness is an independent
risk factor for heart failure in CKD patients (25). In our
study heart failure was more frequently reported in non-BEN
patients who had higher PWV than in BEN patients and
because of that they required more ultrafiltration and more loop
diuretics.
In all decade subgroups PWV values and proportion of
patients with PWV above the cut off values were lower in
BEN than in non-BEN group confirming our presumption
that vascular aging is slower in BEN than in other ESRD
patients. Less obesity, diabetes and milder disturbances in
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TABLE 2 | Hemodynamic characteristics of BEN and non-BEN patients at baseline and follow-up.
Baseline Follow-up
BEN Non-BEN p BEN Non-BEN p
Systolic BP (mmHg) 160 ± 31 155 ± 31 0.308 153 (139–174) 159 (141–172) 0.51
Diastolic BP (mmHg) 85 (77–96) 84 (76–96) 0.60 84 ± 17 84 ± 14 0.99
Mean BP (mmHg) 110 (97–122) 108 (95–122) 0.40 110 ± 21 111 ± 19 0.73
Heart rate (beats/min) 76 ± 13 72 ± 12 0.017 74 ± 13 71 ± 12 0.37
PP (mmHg) 75 ± 20 71 ± 22 0.36 69 (59–83) 75 (61–91) 0.44
Central PP (mmHg) 74 ± 26 77 ± 31 0.47 68.3 (53.7–80.6) 72.4 (57.2–89.5) 0.61
PP amplification −4.75 (−8.56–5.56) −7.2 (−9.45–1.60) 0.06 −4.58 (−8.26–5.31) −7.32 (−9.12–1.8) 0.12
PP amplification ratio 0.92 (0.90–1.08) 0.91 (0.88–1.03) 0.02 0.98 (0.91–1.21) 0.89 (0.87–1.32) 0.01
Central systolic BP (mmHg) 161.4 ± 35.6 157.4 ± 35.0 0.43 158.3 ± 33.2 163.5 ± 34.1 0.45
AIx (%) 38.8 ± 16.5 39.0 ± 15.3 0.93 40.7 ± 15.3 43.4 ± 14.7 0.38
PWV (m/s) 9.2 ± 1.6 10.5 ± 1.9 <0.001 9.3 ± 1.3 10.5 ± 1.9 0.001
adjusted PWV* 9.2 ± 0.2 10.7 ± 0.2 0.004 9.3 ± 0.6 10.7 ± 0.4 0.001
Results are shown as mean ± SD or median (interquartile range); *ANCOVA adjusted as in Model 3, mean ± standard error (SE) BEN, Balkan endemic nephropathy; BP, blood pressure;
Aix, augmentation index; PWV, pulse wave velocity; PP, pulse pressure.
TABLE 3 | Average values of PWV and proportion of BEN and non-BEN patients with PWV values above the cut off for Arteriograph in groups diveded into decades.
Decade (years) BEN (m/s) Non-BEN (m/s) BEN Non-BEN χ2 (p)
N % N %
20–30 – 9.0 (6.9–11.6) 0/0 – 3/5 60 –
30–40 – 9.7 (6.9–12.2) 0/0 – 3/6 50 –
40–50 7.6 10.6 (8.8–13.0) 0/1 0 5/7 71.4 –
50–60 9.7 (8.6–11.5) 10.6 (7.5–13.0) 1/3 33.3 5/11 45.4 0.134 (0.70)
60–70 9.3 (6.7–13.2) 11.2 (7.8–15.7) 10/26 38.4 19/28 67.8 1.435 (0.23)
>70 9.1 (5.9–12.6) 10.6 (7.2–15.1) 18/60 30.0 24/37 64.8 4.296 (0.03)
Total 29/90 32.2 59/96 61.5 5.791 (0.01)
BEN, Balkan endemic nephropathy.
mineral metabolism contributed to lower PWV in BEN patients.
However, in multivariate linear regression models adjusted to
various confounders and risk factors, BEN per se, as a diagnosis,
was the most important negative predictor of increased arterial
stiffness. Early vascular aging and premature CV mortality are
well-known characteristics of CKD starting from early stages (3–
10, 26). Our results on lower PWV, slower increase of arterial
stiffness by aging, slower progression of CKD and lower CV
mortality in BEN patients compared to other ESRD patients
indicate that vascular aging might be slower in BEN, and it
seems that in this aspect BEN is different from other ESRD
and quite contrary to adult polycystic kidney disease could be
considered as a case of slower vascular aging among other CKD
patients. Older age of BEN patients compared to non-BEN
patients when starting with dialysis (67 vs. 57 years) could be
considered as an indicator of slower vascular aging. During the
study period (the same dialytic protocol was applied to both
groups) patients with BEN had better control of hypertension,
calcium, and phosphate which contributed to slower progression
of arterial stiffness i.e., lower PWV at the end of follow-up and
significantly less CV deaths in BEN group than in non-BEN
group (31 vs. 12).
This is the first study which analyzed arterial stiffness and
CV outcome in BEN patients. In this longitudinal study we
confirmed that arterial stiffness and consecutively CV morbidity
and mortality were lower in BEN patients than in other ESRD
patients undergoing dialysis.
Our work has several limitations. First, in this study we have
not enrolled patients in the early phases of BEN. However,
as incidence of BEN is, due to improvement in agriculture
practice, decreasing and disease is diminishing it would be
hard to detect new BEN cases in early phase of CKD (17,
27). Furthermore, our aim was to analyze PWV in ESRD
and compare BEN and non-BEN patients in this CKD stage.
Second, we have enrolled BEN patients from only two BEN
countries (Croatia and Bosnia and Herzegovinia). However, as
the causative agent and the clinical course are the same in
all countries harboring BEN it could be assumed that results
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FIGURE 1 | All-cause (left) and cardiovascular (right) mortality in BEN and non-BEN patients at the end of follow-up. BEN, Balkan endemic nephropathy.
FIGURE 2 | Increased aortic stiffness (PWV) is a strong independent predictor of cardiovascular mortality in non-BEN (left) and in BEN (right) patients undergoing
hemodialysis. BEN, Balkan endemic nephropathy.
from other BEN countries would be the same. Nevertheless,
we are encouraging colleagues from other countries to join
us in this research program. Third, one could argue why
patients with aristolochic acid nephropathy from other world
regions were not included. Due to large amount of toxin
ingested in shorter period of time patients with iatrogenic
aristolochic acid nephropathy, contrary to BEN patients, have
more rapid clinical course and significantly shorter predialytic
period. So, changes on their large vessels would be different from
BEN, an environmental form of aristolochic acid nephropathy
where low doses of aristolochic acid were ingested for decades.
Nevertheless, it will be interesting to analyze arterial stiffness
in this group of patients, particularly from Taiwan and China
where patients sometimes were exposed to smaller amount
of toxin during the longer period of time. Fourth, only
office BP data were analyzed. Unfortunately, we have no
data on ABPM which would additionally improve obtained
results. Fifth, PWV was determined using Arteriograph, device
which is validated and considered reliable (28–30). However,
there are no referral cut off values for CKD patients, so
we used values obtained and determined in hypertensive
patients.
In this study we found slower pulse wave velocity in patients
with BEN compared to other ESRD patients undergoing chronic
hemodialysis and we concluded that vascular aging was slower
and importantly all cause and cardiovascular mortality were
lower in this group of patients comparing to other ESRD
patients. Later onset of hypertension during predialytic clinical
course in BEN and milder forms in advanced stages of CKD
are the most plausible explanations underlying the importance
of strict blood pressure control in all chronic kidney disease
patients starting from early stages. In BEN lower prevalence
of hypertension and milder stages could be attributed to salt-
wasting as a consequence of nephrotoxic effect of aristolochic
acid. Additionally, calcium, phosphate and parathyroid hormone
values were better controlled in BEN patients undergoing chronic
hemodialysis than in non-BEN patients what further lessened the
risk of vascular calcification and progression of arterial stiffness.
BEN could be considered as a model of slower vascular
aging in CKD and a lecture underscoring that good blood
pressure control, adequate control of calcium and phosphate
could significantly slower progression of arterial stiffness leading
to lower all-cause and cardiovascular mortality in chronic kidney
disease.
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